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Cutaneous hyperpigmentation is a common disorder due to excess melanin production by the enzyme
tyrosinase. The gold standard for treatment is hydroquinone (HQ), which reduces pigmentation through its
toxicity to melanocytes rather than via tyrosinase inhibition. We screened an internal library for oligopeptides
that inhibited both mushroom and human tyrosinase but showed no cytotoxicity to human melanocytes. We
identified two highly active inhibitory sequences, P3 and P4, of 8- and 10-amino-acid-length, respectively.
Mushroom tyrosinase inhibition was dose-dependent with IC50 (half-maximal inhibitory concentration) values
of 123 and 40 mM, respectively, compared with 680 mM for HQ. Other oligopeptides showed weaker or no
inhibitory activity. Kinetic studies showed that P3 and P4 are competitive inhibitors of mushroom tyrosinase. At
100 mM, P3 and P4 inhibited human tyrosinase by 25–35%. This inhibition partially depended on whether L-dopa
or L-tyrosine was the substrate, suggesting that tyrosinase may contain contains two distinct catalytic sites.
Treatment of melanocytes with 100 mM P3 or P4 for 7 days led to a 27 or 43% reduction in melanin content. This
inhibition was independent of cell proliferation and cytotoxic effects. Our data suggest that peptide-mediated
inhibition of melanogenesis is due to reduction in tyrosinase activity.
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INTRODUCTION
Melanin, the end product of melanogenesis, determines the
color of human skin, hair, and eyes and is synthesized within
unique membrane-bound organelles called melanosomes.
The type and amount of melanin and its distribution pattern
in the surrounding keratinocytes determine the actual color of
skin (Parvez et al., 2006). Melanogenesis is regulated by
various environmental, hormonal, and genetic factors, such
as UV exposure, a-melanocyte-stimulating hormone, mela-
nocortin 1 receptor, and agouti-related protein (Kadekaro
et al., 2003; Petit and Pierard, 2003). The functions of
melanin include protection of skin from UV radiation, the
inhibition of photocarcinogenesis, and the synthesis of
vitamin D3 (Lindquist, 1973). Hyperpigmentation is a very
common and usually harmless disorder in which patches of
skin become darker in color than the normal surrounding
skin. This darkening occurs when an excess of melanin is
formed and deposited in the skin. The most common
pigmentation disorders for which patients seek treatment
are melasma and post-inflammatory hyperpigmentation (PIH)
(Lynde et al., 2006). These conditions may have a major
impact on a person’s psychological and social well-being,
contributing to lower productivity, social functioning, and
self-esteem (Finlay, 1997).
Melasma is an acquired pigmentary disorder that occurs in
women of all racial and ethnic groups (Rendon et al., 2006).
Although the cause of melasma is unknown, factors include
genetic predisposition, UV light exposure, and estrogen
(Johnston et al., 1998). PIH represents a pathophysiological
response to cutaneous inflammation, such as acne, atopic
dermatitis, lichen planus, chronic dermatitis, and phototoxic
eruptions (allergic reactions to drugs coupled with exposure
to sunlight) (Lacz et al., 2004). Tyrosinase is a multifunctional
copper-containing oxidase, and is considered the key
enzyme orchestrating mammalian melanogenesis (Sanchez-
Ferrer et al., 1995). This key enzyme catalyzes two distinct
reactions in the biosynthesis pathway of melanin: the
hydroxylation of a monophenol (tyrosine) and the conversion
of an o-diphenol (dopa) to the corresponding o-quinone
(dopaquinone). A multitude of different tyrosinase inhibitors
are used today to treat epidermal hyperpigmentation condi-
tions. Skin-whitening agents in the cosmetics industry include
hydroquinone (Jimbow et al., 1974), arbutin (Maeda and
Fukuda, 1996), kojic acid (Cabanes et al., 1994), vitamin C
(Kojima et al., 1995), retinol (Pathak et al., 1986), azelaic
acid (Schallreuter and Wood, 1990), and other botanicals.
The most popular depigmenting agent, hydroquinone
(dihydroxybenzene; HQ), has been in use since 1961. HQ,
with formulations of 2–4%, has been widely used for
melasma treatment and reports of its clinical efficacy have
been well documented (Ennes et al., 2000). HQ inhibits the
conversion of dopa to melanin by inhibiting the activity of
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tyrosinase (Palumbo et al., 1991). In addition to tyrosinase
inhibition, previous studies suggested that HQ exerts its effect
on melanogenesis through degradation of melanosomes and
destruction of melanocytes. It was also found that alteration
of melanosome function, depletion of glutathione, generation
of reactive oxygen species, and subsequent oxidative damage
of membrane lipids and proteins may play a role in the
depigmenting effect of HQ (Briganti et al., 2003). HQ is
considered to be cytotoxic to melanocytes, potentially
mutagenic to mammalian cells (Curto et al., 1999), and
causes skin irritation (Parvez et al., 2006). Owing to the long-
term risk of mutagenesis (DeCaprio, 1999), the use of HQ in
cosmetics has been banned by the European Committee (24th
Dir. 2000/6/EC) and formulations of 4% are available only by
prescription in selected other countries (Solano et al., 2006).
This has led to the use of alternative agents such as kojic
acid and arbutin. However, these agents failed to show
efficacy in vivo, as clinical trials have been disappointing to
date (Curto et al., 1999). The efficacy of these products
appears to be limited due to their adverse effects, poor
skin penetration, and low formulation stability (Hermanns
et al., 2000). More recently, investigators have turned their
attention to short-sequence peptides as potential therapeutic
candidates for the treatment of skin disorders. The most
widely studied and popular signal peptide is the sequence
lysine–threonine–threonine–lysine–serine (KTTKS) found in
type-I procollagen (Katayama et al., 1993). This pentapeptide
has been shown to stimulate feedback regulation of new
collagen synthesis and to result in an increased production of
extracellular matrix proteins such as types I and II collagen
and fibronectin, significantly improving the appearance of
photoaged human facial skin (Robinson et al., 2005; Lupo
and Cole, 2007).
In this study, we screened an internal oligopeptide library
for inhibitory activity against tyrosinase and the absence of
melanocyte toxicity. We discovered several short-sequence
peptides that met both these criteria.
RESULTS
Inhibition of mushroom tyrosinase by oligopeptides
As the rate-limiting enzyme in melanin production, tyrosi-
nase was targeted during the screening of seven potential
hypopigmenting agents (Table 1). Of these oligopeptides, two
showed substantial inhibitory effects on mushroom and
human tyrosinase activity, whereas the other peptides had
either poor or no inhibitory activity on tyrosinase. Dose–
response curves were obtained after an incubation time of
120 minutes (Figure 1). Peptide P6 had no effect on tyrosinase
activity, whereas peptides P1, P2, P5, and P7 showed an
inhibitory effect at high concentrations. On the other hand,
peptides P3 and P4 showed very impressive inhibition at
relatively low concentrations. The IC50 (half-maximal in-
hibitory concentration) for P3 and P4 was 123 and 40 mM,
respectively, compared with 680mM for HQ. Figure 1 also
illustrates that the inhibitory activity of the peptides was dose-
dependent, with P4 showing inhibitory activity at concentra-
tions as low as 50 mM. On the basis of the above results, we
focused our attention on peptides P3 and P4. Figure 2 shows
the time–response curves and indicates that P3 and P4
Table 1. Oligopeptide inhibitory profile against
mushroom tyrosinase
Oligopeptide Sequence IC50 [M]
1
P1 SFLLRN 8 mM
P2 KFEKKFEK 3.6 mM
P3 RADSRADC 123 mM
P4 YRSRKYSSWY 40 mM
P5 PLG 2.73 mM
P6 VLLK No effect
P7 KFEFKFEF No effect
1IC50 [M] is the concentration at 50% inhibition of mushroom tyrosinase
in molar.




























Figure 1. Dose–response curves for all seven peptides and HQ were drawn at 120minutes post incubation with varying concentrations. The experiment
was conducted in a 96-well flat-bottom plate. Each well contained 80ml of 0.067 M potassium phosphate buffer (pH 6.8), 40ml of 5mgml1 L-tyrosine dissolved in 0.067 M
potassium phosphate buffer (pH 6.8), 40ml of the different concentrations of inhibitor in 5% DMSO solution, and 40ml of 480Uml1 mushroom tyrosinase solution.
The assay mixture was incubated at 37 1C and spectrophotometric readings at 475nm were taken every 10minutes. (a) P1, P2, P5, P6, and P7; (b) HQ, P3, and P4.
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exhibited similar inhibitory activity as HQ. Moreover,
peptide P4 showed a more potent inhibitory effect at
concentrations as low as 50 mM.
Kinetics of mushroom tyrosinase inhibition by oligopeptides
We next determined the kinetics of the inhibition for P3, P4,
and HQ using a standard assay (Pomerantz, 1966). The
inhibition mechanisms of the two peptides P3 and P4, as well
as that of HQ, are all competitive as shown by Line-
weaver–Burke plots in Figure 3. The double reciprocal plots
illustrate that Vmax was independent of substrate concentra-
tion for all three inhibitors, whereas the Km was altered. The
inhibition constant (Ki) for HQ, P3, and P4 was determined to
be 0.053, 0.048, and 0.070 mM, respectively.
Inhibition of human tyrosinase by oligopeptides
We also examined the inhibitory activity of P3 and P4 relative
to HQ against human tyrosinase under two conditions: the
first using L-dopa as the substrate and the second using
L-tyrosine as the substrate with L-dopa as the cofactor. In the
latter, L-dopa acts as a hydrogen donor helping eliminate
the lag period observed during tyrosine hydroxylation
(Pomerantz and Warner, 1967). Figure 4 shows dose-
dependent inhibition for P3, P4, and HQ. It can be seen
that P3 and P4 are more potent than HQ at concentrations as
low as 30 mM. At 100mM, human tyrosinase activity was
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Figure 2. Time–response curves for peptides P3, P4, and HQ. The final
volume of each well was 200ml, containing 1 mg ml1 L-tyrosine, 96 U ml1
of mushroom tyrosinase, and varying concentrations of inhibitors, ranging
from 10 mM to 10 mM. The 96-well plate was incubated at 37 1C and the
spectrophotometric readings taken every 10 minutes. Each point on the
graph is an average of five independent trials, displayed with error




















































Figure 3. Lineweaver– Burke plots. (a) P3 (b) P4 and (c) HQ. The
concentration of mushroom tyrosinase [E] was 24 U ml1. The series of
substrate concentrations [S] were 0.05 (or 0.07 for peptide inhibitors), 0.1,
0.15, and 0.2 mg ml1. The series of inhibitor [I] were 0, 0.01, and 0.02 mM.
The results were analyzed according to the Lineweaver–Burke plot method
that allows the determination of the Michaelis constant (Km) and maximum
velocity (Vm). All inhibitors showed a competitive inhibition pattern.
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substrate, P3 was more potent than P4 at inhibiting the
enzyme. On the other hand, when L-tyrosine was used as the
substrate, P4 showed stronger inhibition than P3. These data
support the hypothesis that tyrosinase has two distinct
catalytic sites for L-dopa and L-tyrosine (Olivares et al., 2001).
Effects of HQ, P3, and P4 on melanin content of melanocytes
To determine the effect of the oligopeptides on melanogen-
esis, we incubated melanocytes with HQ, P3, or P4 for 1
week and then measured melanin content. At a concentration
of 10 mM, HQ, P3, and P4 reduced melanin content by 7±2,
22±1, and 40±1%, respectively (Figure 5). At 100 mM, P3
and P4 reduced melanin content by 27±2 and 43±2%,
respectively, whereas HQ was found to be 100% toxic to
melanocytes.
Cytotoxic and proliferative effects of HQ, P3, and P4 on
melanocytes
To exclude the possibility that P3 and P4 were reducing
melanin content by inhibiting cell proliferation or inducing
cytotoxicity, melanocytes were incubated in the presence or
absence of various concentrations of HQ, P3, or P4, and
proliferation was assessed at various time points using the
WST-1 Cell Proliferation Kit (Roche, Palo Alto, CA). Figure 6
shows that treatment with 100mM or greater of HQ
completely abolished WST-1 activity (from 0.45±0.02 at
day 1 down to 0.0 at day 5). These data are consistent with
our above findings and imply that HQ is cytotoxic to
melanocytes at these concentrations. Unlike HQ, 10 mM,
100mM, or 1 mM P3 did not alter melanocyte proliferation
rates relative to the control group. Although no effect on
melanocytes proliferation was observed for P4 at 10 and
100mM after 5 days of incubation, proliferation was inhibited
by 10±2% at a concentration of 1 mM.
Table 2 further supports our findings regarding the toxicity
of HQ on melanocytes compared to peptides P3 and P4. After
a 24-hour incubation of melanocytes with 10 mM HQ,
viability staining with trypan blue indicated that 27% of cells
were dead. This was one order of magnitude greater than that
for P4. The toxic effects of HQ were dose-dependent and at
concentrations of 30 and 100mM, 41 and 98% of melanocytes
were no longer viable, respectively. The highest rate of cell
death for P4 was 18% after incubating the melanocytes with
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Figure 4. Dose–response curves with human tyrosinase. Melanocytes were lysed using 1% Triton X-100 in 0.067 M potassium phosphate buffer (pH 6.8).
Cells were then sonicated twice at 20% intensity for 30 seconds. Lysates were clarified by centrifugation at 10,000 g for 10 minutes after measuring protein
content, an equal amount of 40 mg was added to each well and adjusted with lysis buffer to reach 150 ml. Each triplicate of wells received different
concentrations (0–2 mM) of oligopeptide or HQ. (a) Using L-dopa as the substrate. L-Dopa was dissolved in lysis buffer and added to each well at a final
concentration of 2.5 mM. The plate was incubated at 37 1C for 120 minutes, and spectrophotometric readings at 475 nm were taken at 10 minutes intervals.
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Figure 5. The effects of peptides and HQ on the melanin content of
melanocytes, expressed in pg per cell. The tested concentrations were 1, 10,
and 100 mM. Melanocytes were incubated with test samples for a week.
Cells were lysed and incubated O/N in 1 M NaOH. Melanin content was
determined by comparing the absorbance results with a standard curve
generated from synthetic melanin.
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there was 100% cell death starting within 24 hours of
exposure. P3 was found to be considerably less toxic to
melanocytes even at concentrations as high as 1 mM (2% cell
death after 6 days).
DISCUSSION
In this study, we screened an internal library for oligopeptides
with inhibitory activity against mushroom and human
tyrosinase. Even though the amino-acid sequence similarity
between mushroom and human tyrosinase is only 23%, our
initial experiments were performed using mushroom tyrosi-
nase as earlier studies suggested a strong correlation of
efficacy with agents tested against the human form (Sugimoto
et al., 2003). The peptide dose- and time-response curves
showed that P3 and P4 were 6- and 17-fold more potent
inhibitors of mushroom tyrosinase than HQ (IC50 values
presented in Table 1). On the basis of this initial screen, we
decided to further evaluate and characterize the effects of P3
and P4.
To determine the mode of inhibition, we determined
Lineweaver–Burk plots of P3 and P4 and compared the
kinetics to those of HQ. These studies showed that similar to
HQ, P3 and P4 were competitive inhibitors of tyrosinase.
Peptides P3 and P4 were also tested against fresh extracts of
human tyrosinase. At a concentration of 100 mM, the peptides
were able to inhibit human tyrosinase activity by 25–35%.
Although the potency against human tyrosinase appeared
reduced relative to that observed with mushroom tyrosinase,
several experimental conditions may account for this
discrepancy. First, the assay was carried out on extracts from
lysed melanocytes and not purified human tyrosinase.
Although protease inhibitors were included to reduce
degradation of human tyrosinase, we did not optimize
these conditions. Second, the catalytic site of the extracted
human tyrosinase can exist in different redox states than the
purified form.
We observed a lengthy lag period for tyrosine oxidation.
The oxidation of L-tyrosine by tyrosinase has previously been
characterized by a lag period that is affected by enzyme
and substrate concentration, pH, and hydrogen donors such
as L-dopa (Pomerantz and Warner, 1967). Therefore, when
L-tyrosine was the substrate, L-dopa was added as a cofactor
at low micromolar levels to eliminate this lag period. The
ability to act as substrate requires a free electron donor group,
whereas competitive inhibition, on the contrary, requires the
presence of powerful electron acceptor groups (Passi and
Nazzaro-Porro, 1981). These experiments also unexpectedly
showed that P3 inhibited human tyrosinase more potently in
the presence of L-dopa than L-tyrosine, whereas P4 showed
greater inhibition in the presence of L-tyrosine as the
substrate. Hearing and Ekel (1976) proposed that there are
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Figure 6. Proliferation of human melanocytes treated with HQ, P3, and P4.
A total of 25,000 human melanocytes per well were incubated at 37 1C
in the presence of 10, 100, 1,000 mM HQ, P3, and P4 in Medium 254 for
(a) 1, (b) 3, and (c) 5 days. After the incubation, 10ml WST-1 was added
to each well and absorbance was read at 450 nm after 4 hours incubation
at 37 1C.
Table 2. The toxic effect of HQ, P3, and P4
% Cell death1
Day 1 Day 3 Day 6
Concentration [lM] P3 P4 HQ P3 P4 HQ P3 P4 HQ
1 0 2 10 0 3 12 0 3 10
10 0 3 27 0 6 29 0 5 48
30 0 3 41 0 4 53 0 5 76
100 0 4 98 0 4 100 0 7 100
300 0 6 100 0 11 100 1 9 100
1,000 0 10 100 0 15 100 2 18 100
HQ, hydroquinone.
1Human melanocytes were incubated with HQ, P3, or P4 at the above
concentrations for 1, 3, or 6 days. The mean percentage cell death for at
least three independent runs is shown.
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and another site specific for dopa oxidase activity. Our
findings with P3 and P4 further support the hypothesis of
separate catalytic sites for L-dopa and L-tyrosine (Schallreuter
et al., 2008).
Despite the fact that little is known about the effect of
short-sequence peptides on melanogenesis and tyrosinase
inhibition, there is great potential for these agents to replace
more toxic drugs such as HQ, as they comprise naturally
occurring amino acids that are easily metabolized in skin.
Therefore, risks of systemic absorption and liver-related
mutagenesis may be avoided during the chronic treatment
of hyperpigmentation disorders. Some amino acids such as
L-alanine, glycine, L-isoleucine, and L-leucine have previously
been shown to possess beneficial effects toward disruption of
melanogenesis (Ishikawa et al., 2007). Ishikawa et al.
reported that a combination of these four amino acids had
an additive effect on hypopigmentation similar to that of kojic
acid. Schurink et al. (2007) proposed that the peptide should
contain one or more arginine residues for strong tyrosinase
inhibitory and binding activity. Moreover, their studies
indicated that tyrosinase inhibition is optimal when arginine
and/or phenylalanine is/are combined with hydrophobic
aliphatic residues such as valine, alanine, or leucine. Besides
hydrophobic residues, peptides containing the polar, un-
charged residues cysteine and serine also showed significant
inhibitory activity.
The amino acid tyrosine contains a phenol group, which
makes it unique in that it can serve as a substrate or a
competitive inhibitor. Oligopeptide P3 contains the combi-
nation Arg–Ala in positions 1/2 and 5/6, as well as the amino
acids serine and cysteine at positions 4 and 8, respectively.
The presence of these key residues may explain the strong
inhibitory activity observed for P3. For P4, the presence of
tyrosine at positions 1 and 10, arginine at positions 2 and 4,
and serine at 3, 7, and 8 may explain the robust inhibition
observed for this oligopeptide.
One of the main advantages of oligopeptides P3 and P4 is
the relative absence of melanocyte cytotoxicity (Table 2).
Whereas HQ was 100% toxic after a 24-hour treatment at
100mM, P3 showed no toxic effects after 6 days of treatment.
P4 also showed minimal (7%; Table 2) toxicity after the same
incubation period. Treatment with 1 mM P3 resulted in a 2%
toxicity rate (Table 2) and no effect on melanocyte prolifera-
tion (Figure 6). At a concentration 25-fold higher than its IC50
value, P4 began to show mild (18%; Table 2) melanocyte
toxicity after a prolonged incubation of 6 days. We also
confirmed these findings using proliferation assays, which
showed that HQ was toxic to melanocytes at concentrations
as low as 30 mM (data now shown), whereas mild reduction of
proliferation was first noted only after 3 days of incubation
with 1 mM P4 (Figure 6). Lower concentrations did not show
any effect on melanocyte proliferation even after prolonged
incubation for 5 days, whereas HQ dramatically reduced
melanocyte proliferation within 24 hours at concentrations as
low as 30 (data not shown) and 100mM (Figure 6).
In conclusion, our findings suggest that oligopeptides P3
and P4 may be ideal tyrosinase inhibitors due to their potent
enzymatic inhibitory activity, relative absence of melanocyte
toxicity, and minimal effects on melanocyte proliferation
rates. Further studies are under way to optimize cell
penetration and oligopeptide stability for transdermal
applications. We believe these oligopeptides may hold
significant therapeutic potential for the treatment of skin
hyperpigmentation disorders. As both oligopeptides showed
substantially improved potency against tyrosinase with
minimal melanocyte toxicity, clinical use of these agents
may obviate the need for HQ, which derives its primary skin-
lightening capability through its cytotoxic activity.
MATERIALS AND METHODS
Materials
Mushroom tyrosinase, L-tyrosine, HQ, and L-dopa were purchased
from Sigma-Aldrich (St Louis, MO). The peptides (Table 1) were
synthesized by NeoMPS (San Diego, CA) using solid-phase 9H-
(f)luoren-9-yl(m)eth(o)xy(c)arbonyl chemistry.
Enzymatic assay of mushroom tyrosinase
Tyrosinase inhibition activity was determined in vitro using
L-tyrosine as the substrate using a modified method from Piao
et al. (2002). The concentration of enzyme, substrate, and inhibitor
was denoted as [E], [S], and [I], respectively. The experiment was
conducted in a 96-well flat-bottom plate. Each well contained 80 ml
of 0.067 M potassium phosphate buffer (pH 6.8), 40ml of 5 mg ml1 L-
tyrosine dissolved in 0.067 M potassium phosphate buffer (pH 6.8),
40 ml of the different concentrations of inhibitor in 5% DMSO
solution, and 40 ml of 480 U per ml mushroom tyrosinase solution.
The final volume of each well was 200 ml, containing 1 mg ml1 [S],
96 U ml1 [E], and varying concentrations of [I], ranging from 1mM to
10 mM. For the negative control wells, the inhibitors were substituted
with 5% DMSO solution and adjusted to the total volume of 200 ml.
HQ served as the positive control in our experiments. HQ was tested
in parallel with the oligopeptides at the same concentrations and
same conditions. The assay mixture was incubated at 37 1C. The
optical density of the reaction mixtures, which correlates with the
amount of dopachrome produced, was measured using a spectro-
photometer (Varioskan, Thermo Electron Corporation, Waltham,
MA) at 475 nm and at different time periods.
Kinetic studies
The Lineweaver–Burk plot method was used to determine the
reaction kinetics (Burk et al., 1934). Experiments were conducted
using the same protocol used for measuring mushroom tyrosinase
activity except for changes in concentrations of [E], [S], and [I]. [E]
was 24 U ml1. The series of [S] were 0.05 (or 0.07 for peptide
inhibitors), 0.1, 0.15, and 0.2 mg ml1. The series of [I] were 0, 0.01,
and 0.02 mM. The results were analyzed according to the Line-
weaver–Burk plot method that facilitated the determination of the
Michaelis constant (Km) and maximum velocity (Vmax).
Melanin content measurement
Melanin content of the melanocytes was measured according to the
method of Naeyaert et al. (1991). Human melanocytes were cultured
in 24-well plates and treated with individual test samples for 7 days.
P3, P4, and HQ were tested at 10 and 100 mM each, all in triplicates.
Media were changed every other day and fresh oligopeptide or HQ
was added. After 7 days, the media were discarded and the wells
www.jidonline.org 2247
A Abu Ubeid et al.
Oligopeptide Tyrosinase Inhibitors
were washed with phosphate-buffered saline. Cells were detached
by short incubation in trypsin/EDTA (0.25%/0.1% in phosphate-
buffered saline). An aliquot was used for cell counting and the
remaining cells were sonicated and incubated overnight in dark in
500ml of 1 M NaOH at 37 1C. Melanin concentrations were
calculated by comparison of the optical density at 475 nm of
unknown samples with a standard curve obtained with synthetic
melanin (Sigma-Aldrich). Melanin content was expressed as pg per
cell.
Assay of human tyrosinase activity
The following methods are modifications of protocols adopted from
Nagata et al. (2004) and Cheng et al. (2007). Human melanocytes
were cultured in 100 mm dishes using Medium 254 (Invitrogen,
Carlsbad, CA), incubated at 37 1C in a humidified 5% CO2 chamber.
At 80–90% confluence, cells were harvested and lysed using 1%
Triton X-100 in 0.067 M potassium phosphate buffer (pH 6.8). Cells
were then sonicated twice at 20% intensity for 30 seconds (on ice).
Lysates were clarified by centrifugation at 10,000 g for 10 minutes.
Protein content was determined using a Bio-Rad protein assay kit
(Richmond, CA). Lysates were added to a 96-well flat-bottom plate
containing equal amounts of protein (40 mg), and adjusted with lysis
buffer to reach 150 ml in each well. L-Dopa was dissolved in lysis
buffer and added to each well at a final concentration of 2.5 mM.
Each triplicate of wells received different concentrations (0–2 mM) of
oligopeptide or HQ. The plate was incubated at 37 1C for
120 minutes, and spectrophotometric readings at 475 nm (Varioskan,
Thermo Electron Corporation) were taken at 10 minutes intervals.
In certain experiments, L-tyrosine was substituted for
L-dopa, and used at a final concentration 5 mM in lysis buffer.
L-Dopa was also added at a final concentration of 0.005% to serve as
a cofactor. Several control wells were used in the experiment.
Certain wells served as controls and contained 40mg of protein
extract in lysis buffer, and substrate at varying compositions but
without peptide inhibitors. Other control wells contained lysis
buffer, substrate, peptide inhibitors but no protein extract (no
enzyme).
WST assay for melanocyte proliferation
Melanocyte proliferation was determined using the WST-1 Cell
Proliferation Kit (Roche). Cells were plated at 2.5 104/well in 96-
well plates in a humidified atmosphere with 5% CO2 at 37 1C.
Twenty-four hours after plating, test samples were added and
cultures were incubated for an additional 1, 3, or 5 days. Fresh
medium and test samples were replaced every other day. At the end
of the treatment period, 10 ml WST-1 mixture was added to each well
containing 100ml fresh medium. The plates were placed at 37 1C for
4 hours in the dark and the absorbance at 450 nm was read using the
HTS 7000 Plus Bio Assay reader (Perkin-Elmer, Waltham, MA).
Three replicate wells were measured for each group to be tested.
Wells containing medium but no cells served as background
controls.
Evaluation of the cytotoxic effect of P3, P4, and HQ on
melanocytes
Melanocytes were cultured in three 6-well plates at a density of
4 105 cells per well for 1, 3, or 6 days in 2 ml of Medium 254
containing different concentrations of peptides or HQ (0, 10, 30,
100, 300, or 1,000mM). The plates were incubated at 37 1C in a
humidified 5% CO2 chamber. Media and inhibitors were changed
every 48 hours. After 24 hours, the plate labeled ‘‘Day-1’’ was
harvested and the cells were counted in each well using a
hemacytometer. The control well contained 2 ml of media without
any inhibitor. The toxicity of the test sample was measured
according to the following formula:
½1  ðnumber of cells in control wellÞ  ðnumber of live cells in test sample wellÞ
number of cells in control well
100%
The same procedure was repeated after 72 hours of incubation for the
plate labeled ‘‘Day-3’’ and after 144 hours for the ‘‘Day-6’’ plate.
Statistical analysis
Each experiment was performed in triplicates and run a minimum of
five independent times. The results were averaged, and standard
error of the mean was calculated for all conditions using Microsoft
Excel.
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